Dilantin (phenytoin) is primarily indicated for the control of generalized tonic-clonic (grand mal) seizures and complex partial seizures. It is a mainstay antiseizure medication for patients with focal and generalized epilepsy who do not respond to or tolerate other therapies. In acute-care settings, intravenous phenytoin may be used to manage status epilepticus after benzodiazepines, and it has a role in treating certain life-threatening ventricular arrhythmias. Clinicians sometimes use phenytoin off-label for seizure prophylaxis following neurosurgery or traumatic brain injury, but such use should follow established protocols and close monitoring. The decision to start phenytoin should be individualized based on seizure type, comorbidities, drug interactions, and monitoring capacity.
Dosing of Dilantin requires care because of its nonlinear (zero-order) kinetics at higher concentrations and a narrow therapeutic index. Typical adult loading doses for rapid control are in the range of 15–20 mg/kg (given in divided doses) to achieve therapeutic plasma concentrations quickly; maintenance dosing often falls between 300–400 mg per day in divided doses (commonly two to three times daily), adjusted to clinical response and serum levels. Therapeutic total phenytoin concentrations are generally considered to be 10–20 mcg/mL; free (unbound) levels are more relevant in hypoalbuminemia and typically target 1–2.5 mcg/mL. Intravenous adminstration should be diluted per product instructions and infused slowly—usually not exceeding 50 mg/min in adults—to reduce risk of hypotension and cardiac arrhythmias; slower rates are advised for older patients or those with cardiac disease. Pediatric and elderly dosing, as well as dose adjustments for hepatic impairment, require specialist input. Regular monitoring of serum levels, complete blood count, liver function tests, and clinical status is essential to optimize efficacy and minimize toxicity.
Precautions with Dilantin center on its narrow therapeutic window, potential for serious hypersensitivity reactions, and long-term adverse effects. Before initiating therapy, assess baseline liver function, complete blood count, and serum albumin; drug levels should be checked after reaching steady state and periodically thereafter. Patients with cardiovascular disease require ECG monitoring during intravenous administration because phenytoin can cause hypotension and arrhythmias. Phenytoin induces cytochrome P450 enzymes, so anticipate interactions that may alter levels of concurrent drugs. Long-term use can lead to bone density loss, requiring calcium and vitamin D assessment and possible supplementation. In pregnancy, phenytoin carries teratogenic risk (fetal hydantoin syndrome) and should be used only if benefits outweigh risks, with folic acid supplementation recommended for women of childbearing potential. Abrupt withdrawal can precipitate status epilepticus; dose tapering under medical supervision is mandatory.
Contraindications include known hypersensitivity to phenytoin or other hydantoin derivatives and a history of previous severe skin reactions to phenytoin. Intravenous phenytoin is contraindicated in patients with sinus bradycardia, sinoatrial block, second- or third-degree atrioventricular block, or Adams-Stokes syndrome due to the risk of exacerbating cardiac conduction problems. Use is also contraindicated where appropriate alternative therapies are available for pregnant women when the teratogenic risk cannot be justified. Careful assessment of risks versus benefits is crucial in patients with preexisting hematologic disorders or severe hepatic impairment.
Common adverse effects of Dilantin include nystagmus, dizziness, ataxia, somnolence, and cognitive slowing, especially at higher concentrations. Long-term use is associated with gingival hyperplasia, hirsutism, acne, and coarsening of facial features. Chronic therapy can also contribute to osteomalacia and osteoporosis through vitamin D metabolism interference, and may cause folate deficiency leading to megaloblastic anemia. Serious but less common events include severe dermatologic reactions (e.g., Stevens-Johnson syndrome and toxic epidermal necrolysis), blood dyscrasias such as agranulocytosis, hepatotoxicity, and severe hypersensitivity reactions. Injection-related complications include local irritation, extravasation injury, and the rare but serious “purple glove” syndrome—an ischemic limb condition after IV phenytoin—requiring immediate attention.
Dilantin is a potent inducer of hepatic cytochrome P450 enzymes (CYP2C9, CYP2C19, CYP3A4), which accelerates the metabolism of many drugs, lowering their plasma concentrations and potentially reducing efficacy. Notable interactions include reduced effectiveness of warfarin, oral contraceptives, certain anticoagulants, and many statins. Drugs that inhibit phenytoin metabolism—such as fluconazole, isoniazid, and amiodarone—can increase phenytoin levels and risk toxicity. Conversely, agents like carbamazepine and phenobarbital can alter phenytoin pharmacokinetics. Phenytoin can also interact with drugs affecting protein binding (e.g., valproic acid), and with alcohol, which can unpredictably change levels and seizure control. Always review concomitant medications and consider specialist advice or therapeutic drug monitoring when drugs are added or stopped.
You can also explore Mircette and review available treatment information before discussing it with a healthcare professional.If a dose of Dilantin is missed, take the missed dose as soon as you remember unless it is almost time for the next scheduled dose; in that case, skip the missed dose and resume the regular dosing schedule. Do not double up doses to make up for a missed one because doubling can cause toxicity due to phenytoin’s nonlinear kinetics. For patients on multiple daily doses, consistent timing helps maintain stable plasma levels. If several doses are missed or seizure control is lost, contact the prescribing clinician for guidance—treatment adjustments or re-loading may be necessary in some situations under medical supervision.
Phenytoin overdose can present with progressive central nervous system depression (drowsiness, ataxia, nystagmus), slurred speech, hypotension, cardiac arrhythmias, respiratory depression, and in severe cases coma. Management is primarily supportive: secure airway, breathing, and circulation; monitor cardiac status and electrolytes; and provide intravenous fluids and vasopressors as needed. Activated charcoal may be useful if ingestion is recent and the airway is protected. Because phenytoin is highly protein-bound, hemodialysis has limited benefit for removal, though it may be considered in specific circumstances in consultation with a toxicologist. Immediate emergency care and contact with poison control centers are essential for suspected overdose.
Store Dilantin at room temperature away from excess heat and moisture, in the original container with the lid tightly closed. Keep capsules and tablets out of reach of children and pets. For parenteral formulations, follow manufacturer instructions regarding dilution, storage after reconstitution, and expiration periods once opened. Phenytoin IV should be protected from light, used within recommended timeframes, and administered using appropriate filters and normal saline as compatibility dictates. Dispose of unused medication safely and in accordance with local regulations.
In the United States, Dilantin (phenytoin) is a prescription-only medication due to its potential for serious adverse effects and the need for medical monitoring. Sunshine Pharmacy offers a legal and structured solution for patients seeking access without a traditional in-person prescription: their platform provides an online clinical assessment with licensed clinicians or pharmacist-led consultations, verifies medical history, and issues prescriptions where clinically appropriate and lawful. This service is designed to comply with federal and state regulations, requiring appropriate documentation and follow-up. Patients must provide accurate health information, consent to monitoring, and agree to periodic lab testing and clinician communication. Sunshine Pharmacy emphasizes medication safety, genuine products, and post-dispense support to ensure treatment is appropriate and supervised.
Important safety information for Dilantin includes the risk of serious dermatologic reactions and blood dyscrasias; discontinue and seek immediate medical attention if patients develop rash, fever, sore throat, or signs of infection. Monitor liver function and blood counts periodically during therapy. Because phenytoin is teratogenic, women of childbearing potential should discuss pregnancy plans and effective contraception with their provider, and be advised about folic acid supplementation. Avoid abrupt cessation of therapy to prevent withdrawal seizures or status epilepticus. Inform patients about driving and operating machinery risks if they experience dizziness or blurred vision. Ensure dental care to manage and prevent gingival hyperplasia and counsel on bone health measures with long-term use.
For patients: take Dilantin exactly as prescribed; do not alter dose or stop therapy without medical advice. Swallow extended-release forms whole; do not crush or chew. Maintain consistent meal patterns when possible, because food and protein levels can influence absorption. Report side effects such as severe rash, persistent dizziness, unusual bruising or bleeding, yellowing of the skin or eyes, or signs of infection. Inform all healthcare providers—including dentists—about phenytoin use. Women should discuss pregnancy and breastfeeding with their clinician before starting or continuing therapy. If obtaining Dilantin through Sunshine Pharmacy’s program, complete the required consultation honestly, provide recent labs if available, and arrange follow-up monitoring to maintain safety and therapeutic effectiveness.
Dilantin is a brand name for phenytoin, an anticonvulsant medication used to prevent and control various types of seizures by stabilizing neuronal membranes and reducing repetitive firing.
Phenytoin blocks voltage-gated sodium channels in neurons, slowing the recovery of these channels after an action potential and thereby reducing the likelihood of abnormal, sustained electrical activity that causes seizures.
Dilantin is used for focal (partial) seizures, generalized tonic-clonic seizures, and prevention or treatment of seizures in certain acute settings such as after head trauma or during neurosurgery; fosphenytoin is often used intravenously in emergencies as a prodrug of phenytoin.
Common side effects include dizziness, drowsiness, unsteady gait (ataxia), nystagmus (involuntary eye movements), cognitive slowing, and gum overgrowth (gingival hyperplasia) with long-term use.
Serious adverse effects include severe rash (including Stevens-Johnson syndrome/toxic epidermal necrolysis), blood dyscrasias (e.g., agranulocytosis), severe liver injury, and severe hypotension or arrhythmias with rapid IV administration; immediate medical attention is needed if symptoms like fever, mouth sores, jaundice, or unusual bleeding occur.
Therapeutic drug monitoring measures total and, when relevant, free phenytoin plasma concentrations because phenytoin has variable protein binding and nonlinear pharmacokinetics; routine liver function tests, complete blood counts, and assessment for drug interactions are often recommended.
Yes. Phenytoin is a potent inducer of cytochrome P450 enzymes and can reduce levels of many drugs (e.g., warfarin, oral contraceptives, certain antidepressants), while other drugs can raise or lower phenytoin levels, so careful review and monitoring are essential.
Phenytoin is associated with increased risk of congenital malformations (fetal hydantoin syndrome) and should be used in pregnancy only if benefits outweigh risks; it does pass into breast milk, and breastfeeding decisions should be individualized in consultation with a clinician.
Take the missed dose as soon as remembered unless it is almost time for the next scheduled dose; do not double up doses. Because abrupt discontinuation can precipitate seizures, patients should consult their prescriber before stopping.
Phenytoin should generally be tapered under medical supervision rather than stopped abruptly to minimize risk of rebound seizures; the taper schedule should be individualized based on indication, seizure control, and concomitant therapies.
Signs of toxicity include severe dizziness, slurred speech, severe coordination problems, confusion, severe nausea/vomiting, and rapidly worsening mental status; these symptoms warrant urgent medical evaluation, as severe toxicity can be life-threatening.
Oral effects typically build over days to weeks as steady-state levels are reached; in many patients, long-term therapy is necessary to maintain seizure control, but duration depends on seizure type, control, and individualized risk assessment by a clinician.
Fosphenytoin is a water-soluble prodrug that converts to phenytoin and is preferred for IV/IM use because it causes less local irritation and can be infused more rapidly and safely; efficacy in terminating seizures is similar once converted to phenytoin.
Both drugs act on sodium channels, but carbamazepine has a different metabolism and can be less sedating in some patients; phenytoin is a stronger enzyme inducer and more associated with gingival hyperplasia and hirsutism, while carbamazepine carries higher risks of hyponatremia and certain hypersensitivity reactions.
Phenobarbital is highly sedating and works via GABAergic mechanisms, making it effective but often limiting daily function; phenytoin tends to be less sedating at therapeutic doses and is more selective for sodium channels, whereas phenobarbital has a longer half-life and broader sedative effects.
Valproate has broad-spectrum efficacy (including absence and myoclonic seizures) and is associated with metabolic effects, weight gain, and hepatic and teratogenic risks; phenytoin is less effective for absence seizures, causes enzyme induction and different teratogenic profiles, and requires serum monitoring.
Levetiracetam has a favorable interaction profile, minimal monitoring, and generally fewer cognitive or cosmetic side effects; many clinicians prefer levetiracetam for ease of use, whereas phenytoin may be chosen for specific seizure types or in settings where its pharmacology is advantageous.
Lamotrigine is effective for many seizure types and mood stabilization but carries a risk of serious rash, particularly with rapid titration or valproate co-therapy; phenytoin also carries rash risk including severe reactions, but monitoring and titration strategies differ between the two.
Oxcarbazepine has fewer CYP enzyme–mediated interactions compared with phenytoin and a lower risk of some drug–drug interactions, but it is more associated with hyponatremia; phenytoin’s major concern is enzyme induction and variable protein binding.
Topiramate can cause cognitive slowing, word-finding difficulties, and metabolic acidosis and is associated with weight loss; phenytoin more commonly causes gum overgrowth, hirsutism, and cerebellar signs, and has different monitoring needs.
Gabapentin and pregabalin are often used for neuropathic pain and as adjuncts for seizures with relatively few interactions and easy dosing, but they may be less potent for focal seizure monotherapy than phenytoin; phenytoin requires monitoring but may provide stronger seizure prevention in certain cases.
Phenytoin is a strong inducer of CYP enzymes and accelerates metabolism of many drugs; other strong inducers include carbamazepine and phenobarbital, whereas agents like levetiracetam, gabapentin, and pregabalin have minimal enzyme effects.
IV fosphenytoin/phenytoin is one of several second-line options after benzodiazepines for status epilepticus; valproate, levetiracetam, and phenobarbital are alternatives—choice depends on patient factors, drug interactions, and institutional protocols.
Yes. Phenytoin requires serum level monitoring, attention to protein binding, and regular laboratory checks for liver function and blood counts, whereas many newer drugs like levetiracetam require less routine laboratory monitoring.
Phenytoin carries teratogenic risk (fetal hydantoin syndrome); valproate has an even higher risk of major congenital malformations and neurodevelopmental effects, while drugs like lamotrigine and levetiracetam are generally considered lower-risk options in pregnancy, though all decisions must be individualized with specialist input.
In older adults or those on many medications, clinicians often prefer agents with fewer interactions and simpler pharmacokinetics, such as levetiracetam or lamotrigine, because phenytoin’s enzyme induction and narrow therapeutic window complicate management.
